Previous Next


№1' 2020


International Medical Journal, Vol. 26., Iss. 1, 2020, P. 61−63.



Miroshnik D. M.

Municipal Non−Profit Enterprise of the Kharkiv Regional Council "Regional Clinical Hospital", Kharkiv, Ukraine

Ophthalmic lesions in Sjogren's disease are among the most pronounced, they significantly complicate the patient's life. Along with Sjogren's disease, there is the so−called Sjogren's syndrome, which is a similar lesion of the salivary and lacrimal glands, which develops in 5−25 % of the patients with systemic connective tissue diseases and in 50−75 % with chronic autoimmune diseases. The main sign of damage to the lacrimal glands is the development of dry keratoconjunctivitis, which in severe cases can lead to complications in the form of corneal ulcers, up to the threat of perforation. The study of the effectiveness of various drugs in the treatment of symptomatic therapy showed that the problem of achieving a lasting effect of correction of ophthalmic manifestations has not been currently solved. In order to study the effectiveness of the drug "Encad−Biolik®" (Kharkiv, Ukraine) to stimulate the reparative processes of the cornea as part of the complex therapy of Sjogren's disease were examined 15 patients (30 eyes) who received the drug "Encad−Biolik®" in the form of intramuscular injections and bath phonophoresis. The duration of treatment was 8.0 days, the time of complete epithelialization of the cornea made 7.4 days. In the eyes of two patients who had corneal ulcers, the process was stopped, resulting in a slight cloud−like turbidity. The results of the study demonstrate that the use of the drug "Encad−Biolik®" in the patients with Sjogren's disease was not accompanied by side effects and reduced the duration of corneal epithelialization, duration of treatment, and improved structural results in corneal healing.

Key words: Sjogren's disease, "Encad−Biolik®", cornea, epithelialization.


1. Vasil'ev M. V., Simonova T. N., Safonova T. N. Bolezn' Shegrena: rukovodstvo po vnutrennim boleznyam; revmaticheskie bolezni; pod. red. A. V. Nasonovoї, N. V. Bunchuka. M.: Meditsina, 1997. S. 196−210.

2. Sovremennye podkhody k ispol'zovaniyu glyukokortikoidnykh i tsitotoksicheskikh preparatov pri bolezni Shegrena / V. І. Vasil'ev i dr. // Sovremennaya revmatologiya. 2008. № 2. S. 39−56.

3. Bolezn' Shegrena. Problema rannei diagnostiki i aktual'nost' svoevremennogo lecheniya / T. F. Rogatkіna, A. S. Chernov, N. A. Fofanova, Є. V. Papіchev // Lekarstvennyi vestn. 2016. T. 10, № 3. S. 18−24.

4. Primary Sjögren's syndrome and the eye / O. Bjordal et al. // Surv. Ophthalmol. 2019. Oct 18. pii: S0039−6257(19)30283−8. doi: 10.1016/j.survophthal.2019.10.004

5. The use of autologous serum eye drops for the treatment of ocular surface disorders // E. García−Martín et al. // Eur. J. Hosp. Pharm. 2019. Vol. 26 (6). P. 314−317. doi: 10.1136/ejhpharm−2018−001527

6. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome / P. Brito−Zerón et al. // RMD Open. 2019. Vol. 28, № 5 (2). e001064. doi: 10.1136/rmdopen−2019−001064

7. Hyaluronic Acid as an Alternative to Autologous Human Serum Eye Drops: Initial Clinical Results with High−Molecular−Weight Hyaluronic Acid Eye Drops / R. Beck et al. // Case Rep. Ophthalmol. 2019. Vol. 6, № 10 (2). R. 244−255. doi: 10.1159/000501712

8. Yakimenko S. A., Plevinskis V. P., Andrushkova O.A. Eksperimental'noe obosnovanie primeneniya gidrolizata RNK (Enkad) pri khimicheskikh ozhogakh rogovitsy // Oftal'mologicheskii zhurn. 1990. № 6. S. 338−343.

Go on Top